Skip to main content
. 2018 Jun 22;10(7):211. doi: 10.3390/cancers10070211

Table 1.

Strategies to harness an immune system against AML.

Pathway Therapeutical Action Effect
Type Mechanism
Checkpoint inhibitors PD-1/PD-L1
  • -

    mAb anti-PD-1

  • -

    mAb anti-PD-L1
  • -

    Increased T-cell cytotoxicity

  • -

    Increased DC function as APCs
KIR
  • -

    mAb anti-KIR
  • -

    AML cell lysis
Tolerogenic molecules Arginine
  • -

    human recombinant arginase
  • -

    Prevention of immune tolerance
IDO
  • -

    IDO1-inhibitor
  • -

    Prevention of immune tolerance
Adoptive cell-therapy NK cells
  • -

    adoptive cell therapy
  • -

    AML cell lysis
CAR-T cells
  • -

    adoptive cell therapy
  • -

    AML cell lysis
TCR-edited T cells
  • -

    adoptive cell therapy
  • -

    AML cell lysis
Antigens/Dendritic cells loaded with antigens WT1, RHAMM, PR-3, DC/WT1
  • -

    vaccines
  • -

    Specific AML cell lysis